Acadia Pharmaceuticals (ACAD) Cuts 2026 R And D Guidance, Is It Still 46% Undervalued?
Acadia Pharmaceuticals (ACAD) reduced its 2026 R&D guidance to $355M-$380M, maintaining $956M in cash. Its stock fell 22% in a day and 44% in 90 days, despite analysts estimating a fair value of $30.53, suggesting 46% undervaluation. The company's future hinges on trial results and sales of DAYBUE and NUPLAZID.
How this was made
The 30-second read
Why it matters
The guidance reduction and trial risk triggered a 22% intraday decline, highlighting heightened short‑term downside.
Market read
The news is material for traders with exposure to biotech equities, especially those tracking clinical‑trial outcomes.
What to watch
Potential cash runway and existing product sales (DAYBUE, NUPLAZID) may cushion earnings despite R&D cut.
Background
Acadia Pharmaceuticals (NASDAQ: ACAD) reported quarterly results, cut its 2026 R&D budget to $355‑$380 million, and released new Alzheimer's trial data.
Ticker impact
Acadia Pharmaceuticals announced reduced 2026 R&D guidance and new Alzheimer's trial data, causing a 22% share drop in one day.
likely pressure as the market prices in lower guidance and trial uncertainty
The article reports fresh guidance reduction and trial outcomes that have not been disclosed elsewhere, prompting a sharp price decline.
Market effects
Biotech sector may see broader risk aversion as trial data uncertainty spreads.
U.S. biotech stocks could face heightened volatility in the near term.
Limited to investors tracking neuro‑degenerative drug pipelines.
Counterpoint
If the trial data ultimately proves positive, the stock could rebound sharply from oversold levels.
Key entities
- companyAcadia Pharmaceuticals
Biotech firm developing neurology and rare‑disease drugs.
